Zydus Lifesciences Limited announced the launch of Tishtha™, the world’s first biosimilar for the cancer immunotherapy drug Nivolumab, in India on January 22, 2026. This is targeted at dramatically improving access to advanced oncology treatments by making the therapy available at approximately one-fourth the cost of the reference drug. The company is also pursuing the acquisition of US-based Ardelyx and recently received USFDA approval for its Menkes disease treatment, ZYCUBO®.
Zydus Lifesciences Drives Oncology Access with Nivolumab biosimilar:
Zydus Lifesciences Limited has achieved a major breakthrough in cancer treatment by launching its biosimilar to the cancer immunotherapy drug Nivolumab, known by the brand name Tishtha™, in the Indian market on 22nd January 2026. This comes as a major break-through for the patient community to access major immuno-oncological drugs and is expected to make a drastic difference due to its price, estimated to be a quarter of the cost of the original drug. The drug is to be launched in two forms – 100 mg costing ₹28,950 and 40 mg costing ₹13,950. The company believes that with this new development, more than five lakh (500,000) people in the Indian population may be benefited. The new development comes after a verdict by the Delhi HC, allowing the company to launch the drug, despite its patent of the original Bristol Myers Squibb drug expiring in May 2026.
Strategic Diversification and US Expansion:
Apart from the home oncology market, Zydus Lifesciences is also exploring strategic expansion opportunities. Zydus Lifesciences is reportedly in talks to acquire US biopharmaceutical company Ardelyx Inc., which is expected to be worth approximately $1.6 billion. As a means to facilitate such a potential acquisition, Zydus Lifesciences is also considering a Qualified Institutional Placement of up to ₹5,000 crore, for which the company has already sought approval from its board. Ardelyx currently has two commercial products in the US market, namely IBSRELA and XYPHOZAH, in which IBSRELA is expected to register substantial sales in the years to come.
To add to its expansion plans, Zydus has recently achieved a major milestone through its subsidiary, Sentynl Therapeutics Inc., a US-based subsidiary of Zydus Group. Zydus has successfully gained the U.S. Food and Drug Administration’s (FDA) approval for its product ZYCUBO(R)(Copper Histidinate). According to a mid-January 2026 announcement from Zydus, ZYCUBO(R) has become the first approved medicine for the treatment of a rare neuromuscular condition named Menkes disease affecting children.
Market Context and Valuation:
Zydus Lifesciences finds itself in a fluid pharmaceutical environment. Its share price, therefore, reflects a potential view of investors on the relative strategic initiatives and product pipelines. Market capitalization is around ₹ 88000 crores with a P/E of approximately 18.27 as of January 2026. With Tishtha™, Zydus would be positioned to benefit from the rising demand for biosimilars that are relatively more affordable in an Indian market where advanced cancer treatments have been inaccessible to many because of their costs. The company’s larger strategy has been oncology, rare diseases, and international market expansion through acquisition, indicating a focused approach toward long-term growth and diversification.
Peer Comparison:
Though Zydus Lifesciences is making significant inroads in the oncology and rare diseases market, other leading Indian pharma companies, such as Sun Pharmaceutical Industries and Dr. Reddy’s Laboratories, also have active and focused strategies for augmenting their biologics and specialty divisions. Moreover, the potential acquisition of Ardelyx would further position Zydus among the leading Indian companies who actively target the worldwide specialty and innovative medicine niches, which presently sets them apart from their peers, who have been confined to the production of generics. Nonetheless, Zydus’s first-of-its-kind entry in the Indian biosimilar market with its first biosimilar for Nivolumab and its recent approval for ZYCUBO demonstrate its competitive advantage in certain focused areas of therapeutics.
